Drug Profile


Alternative Names: Aerumab; AERUMAB 11; AR 101 (anti-Pa mAb) - Aridis Pharmaceuticals; AR-101 - Aridis Pharmaceuticals; KBPA-101

Latest Information Update: 06 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Berna Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 13 Nov 2018 Aridis Pharmaceuticals plans a phase II/III trial for Nosocomial pneumonia in 2019
  • 01 Mar 2018 Shenzhen Arimab Biopharmaceuticals will co-promote and co-develop panobacumab (AR 101) in China for Pneumonia
  • 13 Oct 2015 Aridis Pharmaceuticals receives SBIR grant from the National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top